Hypothalamic AMPK as a possible target for energy balance-related diseases

Trends Pharmacol Sci. 2022 Jul;43(7):546-556. doi: 10.1016/j.tips.2022.04.007. Epub 2022 May 12.

Abstract

Hypothalamic AMP-activated protein kinase (AMPK) is a canonical regulator of energy balance and metabolism at the whole-body level. This makes this enzyme an attractive target for treating energy balance-related diseases. However, targeting AMPK within the hypothalamus presents a challenge related to the specific cellular biodistribution of the enzyme and the need to use clinically safe methods of administration. Current evidence has shown that targeting based on small extracellular vesicles (sEVs) might offer a realistic approach for regulating hypothalamic AMPK. This would allow modulation of both sides of the energy-balance equation, namely food intake and energy expenditure, and therefore of overall metabolism. Moreover, this strategy could provide treatment options not only for obesity but also for catabolic/wasting diseases such as hyperthyroidism, rheumatoid arthritis, and even cancer cachexia.

Keywords: AMPK; cancer cachexia; food intake; hyperthyroidism; hypothalamus; obesity; rheumatoid arthritis; thermogenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Anti-Obesity Agents*
  • Eating / physiology
  • Energy Metabolism / physiology
  • Humans
  • Hypothalamus / metabolism
  • Tissue Distribution

Substances

  • Anti-Obesity Agents
  • AMP-Activated Protein Kinases